CAI - Company ID 0002019410
The table below shows Caris Life Sciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $275.36M | $263.71M | $216.17M | $216.83M | $181.40M | $120.92M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $33.84M | $32.36M | $31.32M | $21.62M | $25.05M | $23.07M |
Caris Life Sciences, Inc. reported annual revenue of $812.03M for fiscal year 2025. That is up 97.0% from $412.26M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $69.28M |
| $66.55M |
| $59.71M |
| $51.97M |
| $64.37M |
| $52.12M |
| Operating income | $19.32M | $26.93M | $5.28M | $32.64M | -$17.99M | -$57.95M |
| Income tax | $1.62M | $23.00K | -$134.00K | $0.00 | $0.00 | $0.00 |
| Net income | $15.25M | -$637.00K | -$510.00K | $24.32M | -$71.79M | -$102.58M |
| EPS (diluted) | $0.05 | $0.00 | $0.00 | $0.08 | -$7.97 | -$3.57 |